


## Product Information

**06563 / 06564 Methotrexate (4-Amino-10-methylfolic acid, (+)-Amethopterin, Methylaminopterine, 4-Amino-N<sup>10</sup>-methylpteroyl-L-glutamic acid, Antifolan, N-bismethylpteroylglutamic acid, MTX)**

CAS number: 59-05-2

Appearance:	Yellow powder <sup>3</sup>
Molecular formula:	C <sub>20</sub> H <sub>22</sub> N <sub>8</sub> O <sub>5</sub>
Molecular weight:	454.4 g/mol
Mp:	185-204 °C (dec.) <sup>2</sup>
[α] <sub>D</sub> <sup>20</sup> : 0.1M) <sup>3</sup>	+19 ± 3° (c = 2 in NaOH)
[α] <sub>546</sub> <sup>20</sup> : 0.1M) <sup>3</sup>	+24 ± 3° (c = 2 in NaOH)
pKa1: specified). <sup>4</sup>	3.8 (temperature not specified).
pKa2: specified). <sup>4</sup>	4.8 (temperature not specified).
pKa3: specified). <sup>4</sup>	5.6 (temperature not specified).
Absorbance: 307 nm <sup>2,5</sup>	In 0.1 N HCl: λ <sub>max</sub> = 244 nm,
ε (257nm):	22.3 (0.1 N NaOH) <sup>2</sup>
ε (302nm):	22.7 (0.1 N NaOH) <sup>2</sup>
ε (370nm):	7.3 (0.1 N NaOH) <sup>2</sup>

Storage Temperature -20 °C. Protection from light for long-term storage has been suggested.<sup>4</sup>**Applications:**

MTX, an anticancer drug, is structurally similar to folic acid. MTX (Amethopterin) and aminopterin are both potent, stoichiometric inhibitors of dihydrofolate reductase (DHFR). (Dihydrofolate reductase is an enzyme involved in cellular DNA synthesis.) MTX appears to be preferred to aminopterin (which is photosensitive and toxic). The stability and low toxicity of MTX also favor its use in the selection of hybridomas.<sup>7</sup> The metabolism and pharmacokinetics of MTX have been studied.<sup>8-10</sup> The reaction between MTX and dihydrofolate reductases has been described, and a three-dimensional structure of the complex has been published.<sup>11,12</sup> Resistance to the drug as a result of permeability changes has been studied.<sup>13</sup>

**Preparation Instructions:**

MTX was reported insoluble in water, ethanol, chloroform and ether. It is, however, soluble in solutions of mineral acids and in dilute solutions of alkali hydroxides and carbonates.<sup>4</sup> Compound routinely assayed at 20 mg/mL in NaOH 0.1M.

For cell culture work, a stock solution of the compound methotrexate is prepared using a minimum amount of 1 M NaOH and then diluted with saline or medium. The diluted stock is stable at 4-8 °C for about a week, or at -20 °C for about a month.<sup>6</sup>

**References**

1. Material Safety Data Sheet.
2. *Merck Index*, 12th ed., #6065 (1996).
3. Quality control data (not necessarily specified and regularly tested)
4. *Martindale: the Extra Pharmacopoeia*, 29th ed., p. 636 (1989).
5. Seeger, D.R. et al., *J. Amer. Chem. Soc.*, 71, 1753 (1949).
6. Sigma Biosciences, Cell Culture Division.
7. Horenstein, A.L. et al., *J. Immunological Methods*, 98, 145-149 (1987).
8. Freeman, M.V., *J. Pharmacol Exp. Ther.*, 122, 154 (1958).
9. Henderson, E.S. et al., *Cancer Research*, 25, 1008 and 1018 (1965).
10. Evans, W.E., *Appl. Pharmacokinet.*, p. 518-548 (1980).
11. Sloboda, A.E., *J. Pharmac. Exp. Ther.*, 128, 419 (1960).
12. Matthew, D.A. et al., *Science*, 197, 452 (1977).

13. Mandelbaum-Shavit, F., *Biochim. Biophys. Acta*, 428, 674 (1976).
14. Kumar, P., et al., Interaction of polyglutamyl derivatives of methotrexate, 10-deazaaminopterin, and dihydrofolate with dihydrofolate reductase *Cancer Res.* 46, 5020-5023 (1986)
15. Jansen, G., et al., Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and -resistant leukemia cells. *Adv. Enzyme Regul.* 37, 59-76 (1997)
16. Huennekens, F.M., The methotrexate story: a paradigm for development of cancer chemotherapeutic agents *Adv. Enzyme Regul.* 34, 397-419 (1994)
17. Longo, G. S., et al., g-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylated methotrexate in acute leukemias. *Oncol. Res.* 9, 259-263 (1997)
18. Kumar, P., et al., Inhibition of human dihydrofolate reductase by antifolyl polyglutamates. *Biochem. Pharm.* 38, 541-543 (1989)
19. Sharif, K.A., et al., Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines. *Biochem. Pharm.* 55, 1683-1689 (1998)
20. Rhee, M.S., et al., Characterization of human cellular g-glutamyl hydrolase. *Mol. Pharmacol.* 53, 1040-1046 (1998)
21. Yao, R., et al., Human g-glutamyl hydrolase: cloning and characterization of the enzyme expressed *in vitro*. *Proc. Nat. Acad. Sci. USA* 93, 10134-10138 (1996)